VistaGen Therapeutics (VTGN) reported Q2 revenue
Tweet
Share
E-mailGet Alerts VTGN Hot Sheet
Join SI Premium – FREE
VistaGen Therapeutics (NASDAQ: VTGN) reported Q2 EPS of ($0.54). Revenue for the quarter came in at $258 million.
For earnings history and earnings-related data on VistaGen Therapeutics (VTGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Femasys Inc. (FEMY) Misses Q2 EPS by 20c
- Helius Medical Technologies (HSDT) Misses Q2 EPS by 31c
- Laser Photonics Corporation (LASE) Reports Q2 Loss of $0.08
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
